FBRX
HEALTHCAREForte Biosciences Inc
AI Insight
What's Moving FBRX Today?
No stock-specific AI insight has been generated for FBRX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$9.10$45.36
$44.12
Fundamentals
Market Cap$899M
P/E Ratio—
EPS$-4.58
Dividend Yield—
Dividend / Share—
ROE-188.4%
Profit Margin—
Debt / Equity—
Trading
Volume742K
Avg Volume (10D)—
Shares Outstanding20.5M
FBRX News
22 articles- TRAX Stock Hits All-Time High — What's Driving The Super Rally?Stocktwits·Jul 10, 2026
- FBRX Stock Rallies 78% on Positive Early-Stage Vitiligo Study DataYahoo Finance·Jul 10, 2026
- Forte Biosciences' FB102 Hits Key Goal in Vitiligo Study, Shows Durable ImprovementMarketbeat·Jul 10, 2026
- Forte Biosciences shares surge after positive phase 1b vitiligo resultsProactive Investors·Jul 9, 2026
- FBRX Stock On Track For Biggest Single-Day Gains In 20 Months – What’s Behind The Super Rally?Stocktwits·Jul 9, 2026
- Forte Biosciences Skin Pigmentation Disorder Drug Shows Strong Efficacy, Safety In Early StudyYahoo Finance·Jul 9, 2026
- Forte Biosciences Shares Climb After Positive Phase 1b Vitiligo Trial Results (FBRX)Advfn·Jul 9, 2026
- Enovix, Forte Biosciences rally premarket; PepsiCo slipsYahoo Finance·Jul 9, 2026
- FB102 Achieves Statistically Significant Improvement in Vitiligo at Week 24 After Completion of 12-Week Treatment PeriodYahoo Finance·Jul 9, 2026
- RSU vesting boosts holdings at Forte Biosciences (NASDAQ: FBRX)Stock Titan·Jul 7, 2026
- One Forte Biosciences Insider Raised Stake By 30% In Previous YearYahoo! Finance Canada·Jun 13, 2026
- Millennium Group (FBRX) reports shared control of 1,062,182 sharesStock Titan·Jun 9, 2026
- Forte Biosciences (FBRX) director granted 18,353 RSUs in equity awardStock Titan·Jun 3, 2026
- Forte Biosciences (FBRX) director awarded 18,353 restricted stock units in equity grantStock Titan·Jun 3, 2026
- Forte Biosciences (FBRX) director awarded 18,353 RSUs vesting after 2026 meetingStock Titan·Jun 3, 2026
- Top Midday GainersYahoo Finance·Apr 9, 2026
- Forte Biosciences (FBRX) Upgraded to Buy: Here's What You Should KnowYahoo Finance·Feb 25, 2026
- We Think Forte Biosciences (NASDAQ:FBRX) Can Afford To Drive Business GrowthYahoo Finance·Feb 18, 2026
- Chief Financial Officer of Forte Biosciences Picks Up 30% More StockYahoo Finance·Jan 4, 2026
- Positive week for Forte Biosciences, Inc. (NASDAQ:FBRX) institutional investors who lost 1.7% over the past yearYahoo Finance·Dec 12, 2025
- We're Hopeful That Forte Biosciences (NASDAQ:FBRX) Will Use Its Cash WiselyYahoo Finance·Sep 11, 2025
- This Forte Biosciences Insider Increased Their Holding By 273% Last YearYahoo Finance·Aug 15, 2025
All 22 articles loaded
Price Data
Open$43.60
Previous Close$43.92
Day High$44.37
Day Low$40.11
52 Week High$45.36
52 Week Low$9.10
52-Week Range
$9.10$45.36
$44.12
Fundamentals
Market Cap$899M
P/E Ratio—
EPS$-4.58
Dividend Yield—
Dividend / Share—
ROE-188.4%
Profit Margin—
Debt / Equity—
Trading
Volume742K
Avg Volume (10D)—
Shares Outstanding20.5M
About Forte Biosciences Inc
Forte Biosciences Inc. is a clinical-stage biopharmaceutical company in the United States. The company is headquartered in Torrance, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—